Scarica l'app Stockscreener
5.31
2.95%
-0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.42
Aprire:
$5.19
Volume 24 ore:
9,627
Relative Volume:
0.07
Capitalizzazione di mercato:
$45.21M
Reddito:
-
Utile/perdita netta:
$-30.18M
Rapporto P/E:
-1.9021
EPS:
-2.7916
Flusso di cassa netto:
$-26.29M
1 W Prestazione:
+2.53%
1M Prestazione:
+17.67%
6M Prestazione:
-59.15%
1 anno Prestazione:
-49.64%
Intervallo 1D:
$5.19
$5.285
Intervallo di 1 settimana:
$5.12
$6.09
Portata 52W:
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
5.25 | 46.67M | 0 | -30.18M | -26.29M | -2.7916 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
ATOS Receives Significant Price Target Increase from HC Wainwrig - GuruFocus
Atossa Therapeutics (ATOS) Sees Increased Price Target Following Stock Split - GuruFocus
Aug Weekly: Is Atossa Therapeutics Incs growth already priced in2026 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology - Minichart
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss - GuruFocus
Atossa Therapeutics 2025 Annual Report: (Z)-Endoxifen Clinical Development, Intellectual Property, and Regulatory Strategy - Minichart
Atossa Genetics Investors to Decide on Key Corporate Proposals - AD HOC NEWS
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
ATOS Advances in Drug Development with Strategic Focus - GuruFocus
ATOSSA THERAPEUTICS INC reports Q4 and full year 2025 results and unveils corporate update - Traders Union
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - PR Newswire
Atossa Therapeutics 2025 10-K: $0.0M Revenue; Net loss $34.8M - TradingView
Atossa Therapeutics (NASDAQ: ATOS) boosts cash options but warns on going concern - Stock Titan
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
R&D spending jumps as Atossa (NASDAQ: ATOS) advances (Z)-endoxifen programs - Stock Titan
Atossa Therapeutics (NASDAQ: ATOS) asks shareholders to OK 2:1–20:1 reverse split - Stock Titan
Atossa Therapeutics Inc expected to post a loss of $1.14 a shareEarnings Preview - TradingView
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics Appoints Two New Medical Directors in Breast Oncology and Rare Diseases - Contract Pharma
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - The Globe and Mail
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - PR Newswire
Should I set a stop loss on Atossa Therapeutics Inc2026 Decliners & Growth Focused Stock Pick Reports - baoquankhu1.vn
Atossa Therapeutics announces launch of early-stage DMD program for rare disease awareness - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - Sahm
Atossa presents preclinical data on endoxifen for muscular dystrophy - Investing.com South Africa
Atossa presents preclinical data on endoxifen for muscular dystrophy By Investing.com - Investing.com Australia
Atossa Therapeutics, Inc. Presents Clinical Trial Update On Z-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - marketscreener.com
Atossa Therapeutics shares clinical trial update for Z-endoxifen at MDA conference - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference (2026-03-12) - Seeking Alpha
Big Money Moves: Is Atossa Therapeutics Inc a potential multi bagger2026 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Muscle biomarker improvement reported in dystrophic mice, Atossa Therapeutics asserts - Traders Union
Is Atossa Therapeutics Inc likely to announce a buybackJuly 2025 Momentum & Reliable Entry Point Alerts - baoquankhu1.vn
Hedge Fund Moves: Is Atossa Therapeutics Inc stock undervalued right nowJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
CEO Moves: Is Atossa Therapeutics Inc a speculative investmentQuarterly Market Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Cash from operating activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Cash from financing activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Free cash flow of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Aug Fed Impact: Is Atossa Therapeutics Inc stock undervalued right nowQuarterly Profit Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Total liabilities & shareholders' equities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics advances Z-endoxifen platform in oncology and DMD targeting molecular precision - Traders Union
ATOS PE Ratio & Valuation, Is ATOS Overvalued - Intellectia AI
Is Atossa Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Recap & Daily Profit Focused Screening - mfd.ru
ATOS Should I Buy - Intellectia AI
ATOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atossa Therapeutics outlines Z-Endoxifen strategy for breast cancer prevention - Traders Union
Atossa Therapeutics Launches New $50 Million ATM Program - The Globe and Mail
Atos (ATOS) cuts $100M Jefferies ATM to $0, effective Feb 20, 2026 - Stock Titan
Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts - Defense World
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk - The Globe and Mail
Net debt of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Patterns Watch: What is Atossa Therapeutics Incs TAM Total Addressable Market2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):